Travoprost
- Generic Name
- Travoprost
- Brand Names
- Duotrav, Izba, Travatan
- Drug Type
- Small Molecule
- Chemical Formula
- C26H35F3O6
- CAS Number
- 157283-68-6
- Unique Ingredient Identifier
- WJ68R08KX9
- Background
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure . It is a synthetic prostaglandin F2alpha analog . Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line ...
- Indication
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension .
Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma .
- Associated Conditions
- Increased Intra Ocular Pressure (IOP)
- Associated Therapies
- -
Study of Exchange of Travoprost Intraocular Implant
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT04615403
- Locations
- 🇺🇸
The Eye Associates of Manatee, Manatee, Florida, United States
🇺🇸North Bath Eye Associates, Inc., Petaluma, California, United States
🇺🇸Center for Sight, Sarasota, Florida, United States
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
- Conditions
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT02914509
Stop Retinal Ganglion Cell Dysfunction Study
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 500
- Registration Number
- NCT02390284
- Locations
- 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure
- Conditions
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 60
- Registration Number
- NCT02105311
- Locations
- 🇹🇭
Songklanagarind Hospital, Hatyai, Songkhla, Thailand
Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 14
- Registration Number
- NCT01711177
- Locations
- 🇨🇦
University of Montreal, Montreal, Quebec, Canada
24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- University of Parma
- Target Recruit Count
- 61
- Registration Number
- NCT01655758
- Locations
- 🇮🇹
University Eye Clinic, Parma, Italy
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 196
- Registration Number
- NCT01444040
- Locations
- 🇦🇲
S.V. Malayan Ophthalmological Center, Yerevan, Armenia
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 101
- Registration Number
- NCT01443988
- Locations
- 🇦🇲
S.V. Malayan Ophthalmological Center, Yerevan, Armenia
Effects of Anti-Glaucoma Medications on the Ocular Surface
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 14
- Registration Number
- NCT01315574
- Locations
- 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
- Conditions
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Summa Health System
- Target Recruit Count
- 89
- Registration Number
- NCT00705757
- Locations
- 🇺🇸
Arlington Eye Physicians, Arlington Heights, Illinois, United States
🇺🇸Summa Health System, Akron, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.